Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Leen Ann M.			2. Issuer Name and Ticker or Trading Symbol Allovir, Inc. [ALVR]									5. Relationship of Reporting I (Check all applicable) Director X Officer (give title			10% (Issuer Dwner (specify	
(Last) (First) (N C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500	iddle)	3. Date of Earliest Transaction (Month/Day/Year) 11/12/2021									Chief Scientific Officer						
reet) AMBRIDGE MA 02142		4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature of																	
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Yea	Exec r) if an	2A. Deemed Execution Date, if any (Month/Day/Year)		Tran	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3,			3, 4 and 5) Se Be Ow Fo		Securities Beneficially Owned		Direct ct (I)	7. Nature of ndirect Beneficial Ownership (Instr. 4)	
					Code	v	Am	ount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)					
Common Stock	11/12/2021				S ⁽¹⁾		1	4,266	D	\$22.	2647 ⁽²⁾	2,294,876				See Footnote ⁽³⁾	
Common Stock	11/12/2021				S ⁽¹⁾			500	D	\$23.	1766 ⁽⁴⁾	2,29	4,376			See Footnote ⁽³⁾	
Common Stock	11/15/2021				S ⁽¹⁾) 6,12		5,122	D	\$21.	9155 ⁽⁵⁾ 2,288,25 ⁴		8,254	I		See Footnote ⁽³⁾	
Common Stock	11/16/2021				S ⁽¹⁾	S ⁽¹⁾		100	D	\$21.76		2,288,154				See Footnote ⁽³⁾	
Common Stock													28,000		D		
Tab	le II - Derivati (e.g., pu				-						-	Owne	d				
	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac	Transaction code (Instr. S)		mber ative rities ired osed	6. Date Exercisable and Expiration Date (Month/Day/Year)			nd 7. Ar Se Ur De Se	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
		Code	v	(A)		Date Exerci	sable	Expirati Date		or	ount mber ares						

Explanation of Responses:

- $1. \ This \ sale \ was \ effected \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ on \ December \ 2, \ 2020.$
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$21.81 to \$22.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 3. Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other
- 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$22.99 to \$23.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$21.75 to \$22.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Remarks:

/s/ Brett Hagen, as Attorney-

11/16/2021

in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.